Eli Lilly and Company Q2 Earnings Call Highlights

• The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic

Eli Lilly and Company (NYSE:LLY) reported 48% gross maturation successful the 2nd 4th of 2026, driven chiefly by continued request for its cardiometabolic medicines MOUNJARO and ZEPBOUND, portion raising its full-year gross and net guidance.

Chair and CEO Dave Ricks said the institution delivered maturation crossed cardinal products and large geographies, precocious its pipeline and added assets done concern development. Lilly said its cardinal products accrued by astir $6.8 cardinal during the quarter, portion its oncology, immunology and neuroscience medicines collectively grew 121% from the prior-year period.

→ Meta's Earnings Drop Shows Wall Street Wants More Than Ad Growth

• As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

"We delivered beardown concern results, received regulatory support for caller indications, shared affirmative signifier III proceedings results, added caller medicines to our pipeline, and expanded entree to medicines for patients," Ricks said.

Financial show and updated outlook

Chief Financial Officer Lucas Montarce said second-quarter gross roseate 48% from the aforesaid play successful 2025. MOUNJARO and ZEPBOUND combined for $14.9 cardinal successful revenue, contributing $6.3 cardinal of year-over-year growth.

→ Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling

• 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

Non-GAAP net per stock were $8.38, compared with $6.31 successful the prior-year quarter. The second-quarter fig included $3.03 successful acquired in-process probe and improvement charges. Lilly's non-GAAP show borderline was 54.8%, up 9 percent points from a twelvemonth earlier, portion gross borderline reached 86.3%.